May 11, 2026

What ARVO 2026 Told Us About the Future of Vision Research

Each year, researchers, clinicians, companies, and organizations from around the world gather at the Association for Research in Vision and Ophthalmology (ARVO) meeting to share the latest advances in eye and vision research. This year’s conference in Denver highlighted just how quickly the field is evolving — particularly for inherited retinal diseases (IRDs) and age-related macular degeneration (AMD).

While there is still much work ahead, one message came through clearly: researchers are not only developing more potential treatments, they are also thinking more deeply about how to make those treatments work in the real world and reach more people.

Here are some of the themes and developments that stood out to us from ARVO 2026.

More diseases are moving closer to treatment

Gene therapy continues to be a major area of momentum in IRD research. Several companies and academic groups shared updates from clinical trials for conditions including X-linked retinitis pigmentosa (XLRP), X-linked retinoschisis (XLRS), Stargardt disease, Leber congenital amaurosis (LCA), Usher syndrome, and retinitis pigmentosa (RP).
Researchers also shared updates on emerging approaches for geographic atrophy (GA), including stem cell-based therapies designed to replace damaged retinal pigment epithelial (RPE) cells. While still in early-stage clinical testing, these approaches reflect growing interest in regenerative strategies for retinal disease.

One noticeable shift compared to just a few years ago is the growing number of programs moving into later-stage trials. Researchers are building on lessons learned from earlier gene therapy studies and thinking carefully about issues like long-term safety, surgical delivery, and how to measure meaningful benefit for people living with vision loss.

At the Foundation Fighting Blindness Retinal Therapeutics Innovation Summit, Dr. Eric Pierce reflected on how far the field has come in a relatively short time. He also emphasized that progress in rare disease research is rarely linear, and that even small improvements in vision or slowing disease progression can have a meaningful impact on daily life.

Researchers are tackling the “ultra-rare” challenge

One interesting discussion at ARVO focused on how to develop treatments for people with ultra-rare genetic variants. An ultra-rare mutation impacts very few people (e.g. 100s or 1000s worldwide), in some cases only impacting a single family.

Traditional clinical trials are difficult for very small patient populations, particularly when only a handful of people worldwide may have a specific mutation. Researchers discussed emerging approaches such as “N-of-1” trials, where a treatment is developed and tested for a single individual under carefully regulated conditions.

Several presentations highlighted antisense oligonucleotide (ASO) therapies — highly targeted genetic medicines designed to address specific mutations. Speakers also emphasized the importance of natural history studies and patient registries, which help researchers better understand how diseases progress and how to measure whether a treatment is working.

A recurring theme throughout these sessions was collaboration. Developing treatments for ultra-rare diseases often requires close partnerships between researchers, clinicians, regulators, foundations, and affected families.

While these approaches are aimed at very small patient populations, they are also helping drive innovations that may benefit the broader IRD community, including more flexible clinical trial designs and new genetic treatment technologies.

Success depends on more than the therapy itself

Another major theme was that developing a treatment is only part of the challenge. Researchers are increasingly focused on how therapies are delivered, how success is measured, and whether treatments improve outcomes that matter to people in everyday life.

Several talks focused on the need for better clinical trial endpoints, especially in rare diseases where standard eye chart tests may not fully capture meaningful changes in vision. Researchers discussed newer approaches that measure functional vision and patient-reported benefit, including whether people notice improvements in daily activities or light sensitivity that may not appear on a traditional vision test.

There was also significant discussion about the practical challenges of bringing new technologies into clinical care. In a session focused on artificial intelligence (AI) in ophthalmology, speakers emphasized that promising algorithms alone are not enough. Successful implementation requires trust, collaboration, and integration into real-world healthcare systems.

Low vision and rehabilitation were also an important part of the conversation. One particularly impactful session explored how people with low vision continue to rely heavily on visual reading and how technology, including AI-powered tools, may help improve accessibility and independence.

Looking ahead

ARVO 2026 reinforced that there is no single solution for blindness and vision loss, and that progress will likely come from many different approaches working together.

What was especially encouraging this year was the growing focus on real-world impact: not only developing therapies, but also understanding how to deliver them safely, measure meaningful benefit, and ensure that no community is left behind.

While challenges remain, the level of scientific collaboration, creativity, and momentum across the field continues to provide reasons for hope.